P38 MAP kinase in valve interstitial cells is activated by angiotensin II or nitric oxide/peroxynitrite, but reduced by Toll-like receptor-2 stimulation

Journal of Heart Valve Disease

Volumn 18, Issue 6, 2009, Pages 653-661

  Rabkin, Simon W ^a   Lodhia, Parth ^a   Luong, Michael W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 MORPHOLINO SYDNONIMINE; 3-MORPHOLINO-SYDNONIMINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; DRUG DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; MOLSIDOMINE; NITRIC OXIDE; PEROXYNITROUS ACID; TOLL LIKE RECEPTOR 2;

ANIMAL; AORTA VALVE; ARTICLE; CYTOLOGY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SWINE;

ANGIOTENSIN II; ANIMALS; AORTIC VALVE; ENZYME ACTIVATION; MOLSIDOMINE; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEROXYNITROUS ACID; PHOSPHORYLATION; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; SWINE; TOLL-LIKE RECEPTOR 2;

EID: 77449099066     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Rabkin SW, Chu-Chun-Lin SF. Epidemiology of valvular heart disease in Canada. Can J Cardiol 1988;4:412-416 (Pubitemid 19026146)
2. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-1243 (Pubitemid 36834640)
3. Goldbarg SH, Elmariah S, Miller MA, Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007;50:1205-1213 (Pubitemid 47405136)
4. Rajamannan NM. Calcific aortic stenosis: Lessons learned from experimental and clinical studies. Arterioscler Thromb Vase Biol 2009;29:162-168
5. Akat K, Borggrefe M, Kaden JJ. Aortic valve calcification: Basic science to clinical practice. Heart 2009;95:616-623
6. Rabkin SW. The association of hypertension and aortic valve sclerosis. Blood Pressure 2005;14:264-272 (Pubitemid 41700964)
7. O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002, 106:2224-2230 (Pubitemid 35222217)
8. Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44:1859-1866 (Pubitemid 39424087)
9. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007;21:20-27 (Pubitemid 44921816)
10. Harrison DG, Guzik TJ, Goronzy J, Weyand C. Is hypertension an immunologic disease? Curr Cardiol Rep 2008;10:464-469
11. Arishiro K, Hoshiga M, Negoro N, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007;49:1482-1489 (Pubitemid 46482919)
12. O'Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Invest Med 2004;52:185-191 (Pubitemid 38856421)
13. Olsen MH, Wachtell K, Bella JN, et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol 2004;94:1076-1080 (Pubitemid 39336451)
14. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin- converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-1295 (Pubitemid 39202347)
15. Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 2004;110:1180-1182 (Pubitemid 39202329)
16. Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 2000;91:21-27
17. Ruiz-Ortega M, Esteban V, Ruperez M, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006;15:159-166
18. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vase Biol 2007;27:303-309 (Pubitemid 46143044)
19. Wallby L, Janerot-Sjoberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart 2002;88:348-351
20. Skowasch D, Schrempf S, Wernert N, et al. Cells of primarily extra-valvular origin in degenerative aortic valves and bioprostheses. Eur Heart J 2005;26:2576-2580 (Pubitemid 41677310)
21. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994;23:1162-1170 (Pubitemid 24117151)
22. Kaden JJ, Dempfle CE, Grobholz R, et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005;14:80-87 (Pubitemid 40381303)
23. Wu HD, Maurer MS, Friedman RA, et al. The lymphocytic infiltration in calcific aortic stenosis predominantly consists of clonally expanded T cells. J Immunol 2007;178:5329-5339 (Pubitemid 46595319)
24. Mazzone A, Epistolato MC, De Caterina R, et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in endstage calcified aortic valve stenosis. J Am Coll Cardiol 2004;43:1670-1676 (Pubitemid 38561351)
25. Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Cardiovasc Clin Pract 2009;6:92-199
26. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-680 (Pubitemid 32747155)
27. Meng X, Ao L, Song Y, et al. Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: Potential roles in aortic valve inflammation and stenosis. Am J Physiol Cell Physiol 2008;294:C29-C35
28. Yang X, Fullerton DA, Su X, Ao L, Cleveland JC, Jr., Meng X. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol 2009;53:491-500
29. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-787
30. Akira S. Toll-like receptor signaling. J Biol Chem 2003;278:38105-38108 (Pubitemid 37221695)
31. Ahn KO, Lim SW, Li C, et al. Influence of angiotensin II on expression of toll-like receptor 2 and maturation of dendritic cells in chronic cyclosporine nephropathy. Transplantation 2007;83:938-947 (Pubitemid 46682736)
32. Lv J, Jia R, Yang D, Zhu J, Ding G. Candesartan attenuates Angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. Biochem Biophys Res Commun 2009;380:81-86
33. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869 (Pubitemid 32267078)
34. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912 (Pubitemid 35425238)
35. Kong JY, Rabkin SW. Palmitate induces structural alterations in nuclei of cardiomyocytes. Tissue Cell 1999;31:473-479 (Pubitemid 29531289)
36. Butcher JT, Nerem RM. Porcine aortic valve interstitial cells in three-dimensional culture: Comparison of phenotype with aortic smooth muscle cells. J Heart Valve Dis 2004;13:478-486
37. Rabkin SW, Tsang MY. The action of nitric oxide to enhance cell survival in chick cardiomyocytes is mediated through a cGMP and ERK1/2 pathway while p38 mitogen-activated protein kinasedependent pathways do not alter cell death. Exp Physiol 2008;93:834-842 (Pubitemid 351904252)
38. Rabkin SW, Goutsouliak V, Kong JY. Angiotensin II induces activation of phosphatidylinositol 3-kinase in cardiomyocytes. J Hypertens 1997;15:891-899 (Pubitemid 27344854)
39. Kong JY, Klassen SS, Rabkin SW. Ceramide activates a mitochondrial p38 mitogen-activated protein kinase: A potential mechanism for loss of mitochondrial transmembrane potential and apoptosis. Mol Cell Biochem 2005;278:39-51 (Pubitemid 41430110)
40. Feelisch M, Ostrowski J, Noack E. On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol 1989;14(suppl. 11):S13-S22 (Pubitemid 20313485)
41. Klassen SS, Rabkin SW. The metalloporphyrin FeTPPS but not cyclosporin A antagonizes the interaction of peroxynitrate and hydrogen peroxide on cardiomyocyte cell death. Naunyn-Schmiedeberg's Arch Pharmacol 2009;379:149-161
42. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR. Novel homologues of CSBP/p38 MAP kinase: Activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997;235:533-538 (Pubitemid 27326515)
43. Young PR, McLaughlin MM, Kumar S, et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997;272:12116-12121 (Pubitemid 27202792)
44. Chester AH, Taylor PM. Molecular and functional characteristics of heart-valve interstitial cells. Philos Trans R Soc London - B: Biol Sci 2007;362:1437-1443 (Pubitemid 47201768)
45. Liu AC, Joag VR, Gotlieb Al. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 2007;171:1407-1418 (Pubitemid 350158303)
46. Bao W, Behm DJ, Nerurkar SS, et al. Effects of p38 MAPK Inhibitor on angiotensin H-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 2007;49:362-368 (Pubitemid 47000310)
47. Pellieux C, Sauthier T, Aubert JF, Brunner HR, Pedrazzini T. Angiotensin II-induced cardiac hypertrophy is associated with different mitogenactivated protein kinase activation in normotensive and hypertensive mice. J Hypertens 2000;18:1307-1317
48. Rabkin SW, Sunga PS, Sanghera JS, Pelech SL. Reduction of angiotensin H-induced activation of mitogen-activated protein kinase in cardiac hypertrophy. Cell Mol Life Sci 1997;53:951-959 (Pubitemid 28021510)
49. Chan SHH, Hsu K-S, Huang C-C, Wang L-L, Ou C-C, Chan JYH. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla (see comments). Circ Res 2005;97:772-780 (Pubitemid 41447127)
50. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: A mechanism for activation of latent TGF-betal. Am J Physiol - Renal Physiol 2004;286:F278-F287 (Pubitemid 38141671)
51. Touyz RM, He G, El Mabrouk M, Diep Q, Mardigyan V, Schiffrin EL. Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by ATI receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. J Hypertens 2001;19:553-559 (Pubitemid 32280947)
52. Wei C, Cardarelli MG, Downing SW, McLaughlin JS. The effect of angiotensin II on mitogen-activated protein kinase in human cardiomyocytes. J Renin-Angiotensin-Aldosterone Syst 2000;1:379-384
53. Guo R-W, Yang L-X, Li M-Q, Liu B, Wang X-M. Angiotensin II induces NF-kappa B activation in HUVEC via the p38MAPK pathway. Peptides 2006;27:3269-327.
54. Matsuoka H, Arai T, Sho Goya HK, et al. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002;283:L103-L112 (Pubitemid 34764546)
55. Wenzel S, Taimor G, Piper HM, Schluter KD. Redox-sensitive intermediates mediate angiotensin H-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. FASEB J 2001, 15:2291-2293
56. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005;23:97-104 (Pubitemid 40128986)
57. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA. Endothelial dysfunction and peroxynitrite formation are early events in angiotensininduced cardiovascular disorders. FASEB J 2000;14:271-278 (Pubitemid 30086064)
58. Koppenol WH. The basic chemistry of nitrogen monoxide and peroxynitrite. Free Radical Biol Med 1998;25:385-391 (Pubitemid 28390296)
59. Uppu RM, Nossaman BD, Greco AJ, et al. Cardiovascular effects of peroxynitrite. Clin Exp Pharmacol Physiol 2007;34:933-937 (Pubitemid 47083961)
60. Van der Vliet A, Smith D, O'Neill CA, et al. Interactions of peroxynitrite with human plasma and its constituents: Oxidative damage and antioxidant depletion. Biochem J 1994;303:295-301 (Pubitemid 24302933)
61. Lin KT, Xue JY, Sun FF, Wong PY. Reactive oxygen species participate in peroxynitrite-induced apoptosis in HL-60 cells. Biochem Biophys Res Commun 1997;230:115-119 (Pubitemid 27210254)
62. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991;288:481-487
63. Oh-hashia K, Maruyamaa W, Yia H, Takahashib T, Naoic M, Isobe KI. Mitogen-activated protein kinase pathway mediates peroxynitrite-induced apoptosis in human dopaminergic neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun 1999;263:504-509
64. Upmacis RK, Deeb RS, Resnick MJ, et al. Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells Am J Physiol Cell Physiol 2004;286:C1271-C1280 (Pubitemid 38649977)
65. Shao B, Bergt C, Fu X, et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCAl-dependent cholesterol transport. J Biol Chem 2005;280:5983-5993 (Pubitemid 40280082)
66. Turko IV, Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev 2002;54:619-634 (Pubitemid 35351199)
67. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424 (Pubitemid 46217686)
68. Chi H, Flavell RA. Acetylation of MKP-1 and the control of inflammation. Science Signaling (Electronic Resource) 2008;1:pe44
69. Rojo F, Gonzalez-Navarrete I, Bragado R, et al. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 2009;15:3530-3539
70. Ruby J, Rehani K, Martin M. Treponema denticola activates mitogen-activated protein kinase signal pathways through Toll-like receptor 2. Infect Immunity 2007;75:5763-5768 (Pubitemid 350207815)
71. Sun Y, Ishibashi M, Seimon T, et al. Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res 2009;104:455-465
72. Bainbridge BW, Darveau RP. Porphyromonas gingivalis lipopolysaccharide: An unusual pattern recognition receptor ligand for the innate host defense system. Acta Odont Scand 2001;59:131-138 (Pubitemid 33644361)
73. Liu AC, Gotlieb AI. Transforming growth factorbeta regulates in vitro heart valve repair by activated valve interstitial cells. Am J Pathol 2008;173:1275-1285
74. Sakai A, Han J, Cato AC, Akira S, Li JD. Glucocorticoids synergize with IL-lbeta to induce TLR2 expression via MAP Kinase Phosphatase-1-dependent dual inhibition of MAPK JNK and p38 in epithelial cells. BMC Mol Biol 2004;5:2.
75. Kiani AN, Fishman EK, Petri M. Aortic valve calcification in systemic lupus erythematosus. Lupus 2006;15:873-876 (Pubitemid 46044919)
76. Stanton L-A, Beier F. Inhibition of p38 MAPK signaling in chondrocyte cultures results in enhanced osteogenic differentiation of perichondral cells. Exp Cell Res 2007;313:146-155 (Pubitemid 44958460)
77. Simmons C A, Matlis S, Thornton AJ, Chen S, Wang CY, Mooney DJ. Cyclic strain enhances matrix mineralization by adult human mesenchymal stem cells via the extracellular signal-regulated kinase (ERK1/2) signaling pathway. J Biomech 2003;36:1087-1096 (Pubitemid 36794104)
78. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005;112:1229-1234